Roche’s drug with chemo reduces disease worsening due to bladder cancer
Category: #healthcare  By Akshay Kedari  Date: 2019-08-05
  • share
  • Twitter
  • Facebook
  • LinkedIn

Roche’s drug with chemo reduces disease worsening due to bladder cancer

· Outputs would be shared globally with healthcare authorities at the next medical meeting.

· While encouraging survival results were observed, the data isn’t mature enough and a follow-up would continue up until next planned analysis.

Roche Holding AG, a Swiss multinational healthcare company, has reportedly announced that the IMvigor130 phase 3 study has met its co-primary final point of investigator assessed progression free survival (PFS).

The combination of chemotherapy based on platinum with Tencentriq resulted in a substantial reduction in the risk of death or disease worsening in people with formerly untreated locally advanced or metastatic urothelial carcinoma (mUC) in comparison with chemotherapy only.

Safety in the chemotherapy plus Tencentriq seemed to be consistant with all the safety profiles currently known that was used for individual medicines and no other new safety signals were taken for this particular combination.

Outputs would be shown in the next medical meeting and shared with healthcare officials across the globe, which would also include the European Medicines Agency (EMA) and United States Food and Drug Administration (FDA).

Chief Medical Officer and Head of Global Product Development, Sandra Horning, M.D. stated that IMvigor130 is the very first positive Phase 3 study for cancer immunotherapy combination in previously untreated developed bladder cancer, a fast growing disease having high unmet wants. Horning also stated that the outcomes bolster the company's vast clinical development program for Tencentriq in untreated bladder cancer, and the company's approach to mix immunotherapy with other medicines or chemotherapy to improve patient results.

Tencentriq is the first cancer immunotherapy permitted in bladder cancer. Presently, four studies are being conducted in phase 3 examining Tencentriq individually and in combination with some different medicines in advanced and early bladder cancer.

Roche has an expansive development program for Tencentriq, which also includes planned and multiple ongoing Phase 3 trials, through skin, lung, genitourinary, gastrointestinal, breast, gynecological, neck and head cancers. This includes studies on examining Tencentriq with other medicines and alone as well.

Source Credit: https://www.globenewswire.com/news-release/2019/08/05/1896628/0/en/Roche-s-Tecentriq-plus-platinum-based-chemotherapy-reduced-the-risk-of-disease-worsening-or-death-in-people-with-previously-untreated-advanced-bladder-cancer.html

About Author

Akshay Kedari    

Akshay Kedari

Akshay holds a Bachelor’s degree in computer engineering. Despite having a penchant for software development and the like, Akshay took to writing as a career owing to his passion for the field. Presently, Akshay writes articles for itresearchbrief.com and a few oth...

Read More>>

More News By Akshay Kedari

Momotaro doses first patient with MTG201 in its Phase 2 clinical trial
Momotaro doses first patient with MTG201 in its Phase 2 clinical trial
By Akshay Kedari

The Phase 2 study will register approx. twelve patients diagnosed with malignant mesothelioma that...

Servier, Ipsen release initial Phase II/III clinical data of ONIVYDE®
Servier, Ipsen release initial Phase II/III clinical data of ONIVYDE®
By Akshay Kedari

The results from the Phase II/III trials, which involved efficacy data and preliminary safety, was p...

Ceridian inks an agreement to acquire WFM solution provider RITEQ
Ceridian inks an agreement to acquire WFM solution provider RITEQ
By Akshay Kedari

The acquisition would advance Ceridian’s momentum in New Zealand and the Australian markets. ...